Compare Amgen, Inc. (AMGN) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs SpaceX — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while SpaceX trades at $143.2 (market cap $1.92T). The key difference: SpaceX is far larger — about 9.8× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| AMGN | SPCX | |
|---|---|---|
Market Cap | $196.12B | $1.92T |
Sector | Health | Technology |
52-Week High | $388.16 | $202.09 |
52-Week Low | $271.18 | $135.00 |
Enterprise Value | $241.41B | $1.93T |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SPCX trades at $145.44, down 4.42% today, with neutral technical signals and mixed fundamentals. The company reported Q1 2026 EPS of -$1.10, missing expectations, while revenue grew to $18.67B in 2025. Despite negative profitability metrics, analyst consensus remains bullish with a $239.67 price target. Recent Nasdaq-100 inclusion and Starmind AI project announcements highlight growth potential amid significant cash burn from heavy investing activities.
SPCX presents high-risk, high-reward potential with ambitious AI and space infrastructure projects driving long-term optimism. However, negative margins, rich valuations, and upcoming share unlocks pose substantial downside risks. The stock's future hinges on successful execution of Starlink monetization and AI data center initiatives against intense competition and capital intensity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
